Navigation Links
New drug cuts risk of deadly transplant side effect in half
Date:12/9/2012

ANN ARBOR, Mich. A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center.

The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 21 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone.

Results of the study will be presented Dec. 9 at the 54th Annual Meeting of the American Society of Hematology.

"Graft-vs.-host disease is the most serious complication from transplant that limits our ability to offer it more broadly. Current prevention strategies have remained mostly unchanged over the past 20 years. This study has us cautiously excited that there may be a potential new way to prevent this condition," says lead study author Sung Choi, M.D., assistant professor of pediatrics at the U-M Medical School.

Vorinostat is currently approved by the U.S. Food and Drug Administration to treat certain types of cancer. But U-M researchers, led by senior study author Pavan Reddy, M.D., found in laboratory studies that the drug had anti-inflammatory effects as well which they hypothesized could be useful in preventing graft-vs.-host disease, a condition in which the new donor cells begin attacking other cells in the patient's body.

Choi will present data on the first 47 patients enrolled on the study at the University of Michigan Comprehensive Cancer Center and Washington University. Participants were older adults who were undergoing a reduced-intensity bone marrow transplant with cells donated from a relative. Patients received standard medication used after a transplant to prevent graft-vs.-host disease. They also received vorinostat, which is given as a pill taken orally.

The researchers found vorinostat was safe and tolerable to give to this vulnerable population, with manageable side effects. In addition, rates of patient death and cancer relapse among the study participants were similar to historical averages.

The results mirror those found in the laboratory using mice. Reddy, an associate professor of internal medicine at the U-M Medical School, has been studying this approach in the lab for eight years.

"This is an entirely new approach to preventing graft-vs.-host disease," Choi says. Specifically, vorinostat targets histone deacetylases, which are different from the usual molecules targeted by traditional treatments.

"Vorinostat has a dual effect as an anti-cancer and an anti-inflammatory agent. That's what's potentially great about using it to prevent graft-vs.-host, because it may also help prevent the leukemia from returning," Choi says.

The study is continuing to enroll participants. The researchers hope next to test vorinostat in patients receiving a transplant from an unrelated donor, which carries an even greater risk of graft-vs.-host disease. This approach is not currently available outside of this clinical trial.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert  

Related medicine news :

1. Scientists uncover multiple faces of deadly breast cancer
2. Pacemakers, Defibrillators Sources of Deadly Infections: Study
3. Mens Breast Cancer Often More Deadly, Study Suggests
4. MSU plan would control deadly tsetse fly
5. Markey receives $6.25 million to study deadly blood and bone marrow disease
6. Tylenol Overdose Can Be Deadly for a Child
7. UW research shows new prognosis tool for deadly brain cancer
8. Deadly Black Widow Spider Edged Aside in California
9. Tornadoes Dont Have to Be Deadly, Experts Say
10. UT Southwestern study suggests new treatment target for deadly brain tumors
11. AuCoin gets $600,000 to refine new test for deadly bacterial infection melioidosis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New drug cuts risk of deadly transplant side effect in half
(Date:1/18/2017)... ... , ... At Hallmark Nameplate, their commitment to quality is what sets them ... 13485. This certification is another way they are making constant strides to provide all ... need. , The ISO 13485 Certification is a major accomplishment for Hallmark Nameplate and ...
(Date:1/18/2017)... ... January 18, 2017 , ... Michael J. Hennessy ... for its Center for Biosimilars, announced Michael J. Hennessy Associates, Inc. President Michael ... field of biosimilars through thought leader interaction in, live video and interactive digital ...
(Date:1/18/2017)... ... 18, 2017 , ... During pregnancy, women are at an ... those dental problems can increase the risk of pregnancy complications. Unfortunately, according to ... to get the dental care they need. Agoura Hills dentist, Philip Shindler ...
(Date:1/17/2017)... , ... January 17, 2017 , ... Anesthesia Progress ... for dentists to choose the best drug option for each patient. Dentists have several ... and better overall outcomes. , Researchers from the Tokyo Dental College in Tokyo, Japan ...
(Date:1/17/2017)... ... 17, 2017 , ... For breast cancer clinicians and researchers who were unable ... a more intimate review and analysis of its highlights, a novel half-day, complimentary meeting—the ... by Imedex on February 4, 2017 in Chicago. Chaired by Kathy S. Albain, MD, ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Dermata Therapeutics, LLC, ... to treat a variety of dermatological diseases, announces ... DMT210, in a Phase 2 acne rosacea study. ... downregulate the proinflammatory cytokines in the skin responsible ... rosacea. This clinical trial, DMT210-003, ...
(Date:1/18/2017)... Safe Rx LLC and Good Day Pharmacy, ... Loveland, Colorado , today announced the availability ... Day locations.     "Patients with prescriptions prone ... storage," said Milton Cohen , President & CEO ... a cup of coffee, you can protect your children ...
(Date:1/18/2017)... In China , we say Health is ... China,s Healthy Strategy originates. 2016 is ... and Social Development of the People,s Republic of ... council of the People,s Republic of China ... plan, identifying medical devices as one of the main breakthrough ...
Breaking Medicine Technology: